Gregory K. Bergey, MD, is professor of neurology at The Johns Hopkins University School of Medicine in Baltimore, Maryland, where he is also director of The Johns Hopkins Epilepsy Center, vice chair for Neurological Laboratories, and codirector of the Epilepsy Research Laboratory. He is a member of the Epilepsy Foundation Research Council, the National Institutes of Health (NIH) NST Training and Career Development Study Section, and has served on the Board of Directors of the American Epilepsy Society (AES) and other NIH study sections. In addition to serving as a reviewer for a number of journals, Dr. Bergey is chief editor, clinical science, Epilepsy Currents. He has been involved in numerous clinical trials of investigational treatments for epilepsy, and the NIH-funded research projects he participates in at the Epilepsy Research Laboratory involve patterns of seizure onset, propagation and cessation of seizures, and investigations into computer-simulated neural networks. His clinical interests are intractable epilepsy, primary generalized seizure disorders, and epilepsy in special populations.
 
  

Amy R. Brooks-Kayal, MD, is professor of pediatrics and codirector of the Translational Epilepsy Research Program, University of Colorado, Denver School of Medicine, as well as director of child neurology and Ponzio family chair in pediatric neurology, The Children’s Hospital, Denver. Dr. Brooks-Kayal’s research focuses on the effects of early-life seizure activity on the development of neurotransmitter systems in the immature brain. Her work has particular emphasis on the role of GABAA receptors in development and epileptogenesis, a topic on which she lectures extensively and has been widely published. An active member of several professional and scientific societies, Dr. Brooks-Kayal is a member of the Board of Directors for the AES and served as the chair of the Scientific Program Committee in 2005. She has also served as a member of multiple other AES committees and as a member of the NIH Clinical Neurosciences and Disease study section. Dr. Brooks-Kayal was previously on the program committee for the Society for Neuroscience and the organizing committee for the NIH Curing Epilepsy 2007 Conference. She is past associate editor of developmental and pediatric epilepsy content for Epilepsia.
 
   Jacqueline A. French, MD, is a professor in the Department of Neurology, and member of the New York University Comprehensive Epilepsy Center. Dr. French trained in neurology at Mount Sinai Hospital in New York and completed her fellowship training in electroencephalogram (EEG) and epilepsy at Mount Sinai Hospital and Yale University. Dr. French has focused her research efforts on the development of new therapeutics for epilepsy. She is director of the Epilepsy Study Consortium, and is codirector of a biannual symposium on trial design and its implications. She has written many articles, editorials, and chapters and has edited 2 books on the subject. Dr. French has also been active in creating practice parameters, serving on committees of the American Academy of Neurology (AAN) and the AES, and chairing several practice parameter task forces. She has served on the board of the AES and the American Society of Experimental Therapeutics and is the 2005 recipient of the AES Service Award. Dr. French is the head of the scientific advisory board of the Epilepsy Therapy Development Project, a private group devoted to the development of new epilepsy therapies, and serves as chair of the North American Commission of the International League Against Epilepsy.
 
   Gregory L. Holmes, MD, is professor of neurology and pediatrics and chairman of neurology at Dartmouth Medical School in Hanover, New Hampshire. He is widely published as a researcher focusing on the delineation, effects, and treatment of pediatric/developmental epilepsy. In addition to being active in professional society and hospital committees, Dr. Holmes has served on the editorial boards of 8 epilepsy journals, has been on multiple NIH study sections, and has lectured internationally at hospitals, medical schools, and major epilepsy and neurology associations. He is past president of the AES. Dr. Holmes also serves as a doctor for Camp Wee-Kan-Tu, a camp for children with epilepsy in Massachusetts.
 
  

Ilo E. Leppik, MD, is director of research of MINCEP Epilepsy Care in Minneapolis and professor of pharmacy and adjunct professor of neurology at the University of Minnesota. Dr. Leppik is the past president of the AES and the past chairman of the AES Guidelines Task Force and the Central Society for Neurological Research. He was the founding and managing editor of Epilepsy Research from 1986-2006. He also was on the board of directors of the Epilepsy Foundation of America and chaired its professional advisory board. Currently, Dr. Leppik is principal investigator of a multicenter study of epilepsy in the elderly. His research is widely published, and he has authored or coauthored a number of books, including Contemporary Diagnosis and Management of the Patient With Epilepsy. He is the recipient of the 2007 William G. Lennox Award from the AES.

 
Page   

Page B. Pennell, MD, is director of research, Division of Epilepsy, Department of Neurology, Brigham and Women’s Hospital, an affiliate of Harvard Medical School. She was previously an associate professor of neurology at Emory University School of Medicine, where she served as director of the Emory Epilepsy Program. She received her MD from the University of Florida, Gainesville. Dr. Pennell has served on the editorial boards for Epilepsia and The Neurologist and as a contributing editor for Epilepsy Currents. Dr. Pennell has also published more than 50 papers in her field. She is a fellow of the American Neurological Association, and a member of the AES and the AAN. In the AES, she has served as chair of the Clinical Therapeutics Committee. For the AAN, she has served as a speaker and course director at the annual meeting and on the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee that provided the Practice Parameter update on pregnancy in women with epilepsy. Dr. Pennell’s primary research interests are on gender-specific issues for women with epilepsy. Other areas of research interest include pharmacokinetics, pharmacodynamics, and pharmacogenetics of antiepileptic drugs, and investigational drug and device trials for medically refractory epilepsy.
 
Michael    Michael D. Privitera, MD, is professor of neurology and director of the Cincinnati Epilepsy Center at the University of Cincinnati Medical Center in Ohio. During his fellowship in epilepsy and EEG at the University of Texas Southwestern Medical School, he was awarded the Wilder Penfield Research Award from the AES for his work with antiepileptic drug pharmacology. He is treasurer of the AES. Dr. Privitera has coauthored many scientific publications in the area of epilepsy. He recently authored a book, Clinician’s Guide to Antiepileptic Drug Use. Dr. Privitera is the recipient of several NIH contracts and has been a principal investigator or investigator for more than 40 different protocols for the study of investigational antiepileptic drugs.